Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Alexion Pharm Inc (ALXN)

Alexion Pharm Inc (ALXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,579,278
  • Shares Outstanding, K 219,848
  • Annual Sales, $ 6,070 M
  • Annual Income, $ 603,400 K
  • 60-Month Beta 1.23
  • Price/Sales 5.45
  • Price/Cash Flow 6.59
  • Price/Book 2.85
Trade ALXN with:

Options Overview

Details
  • Implied Volatility 27.33%
  • Historical Volatility 14.64%
  • IV Percentile 17%
  • IV Rank 6.61%
  • IV High 75.57% on 03/18/20
  • IV Low 23.92% on 01/20/21
  • Put/Call Vol Ratio 0.63
  • Today's Volume 75
  • Volume Avg (30-Day) 776
  • Put/Call OI Ratio 2.29
  • Today's Open Interest 11,369
  • Open Int (30-Day) 14,572

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 2.87
  • Number of Estimates 7
  • High Estimate 3.24
  • Low Estimate 2.54
  • Prior Year 3.02
  • Growth Rate Est. (year over year) -4.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
146.97 +1.01%
on 03/04/21
158.56 -6.37%
on 02/12/21
-7.13 (-4.58%)
since 02/04/21
3-Month
116.61 +27.31%
on 12/09/20
162.60 -8.70%
on 01/26/21
+27.95 (+23.19%)
since 12/04/20
52-Week
72.67 +104.29%
on 03/16/20
162.60 -8.70%
on 01/26/21
+51.24 (+52.71%)
since 03/04/20

Most Recent Stories

More News
Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that three abstracts have been accepted for presentation at the 73rd annual meeting of the American Academy of Neurology (AAN), taking place...

ALXN : 148.46 (+0.18%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - CLGX, CATM, CHNG, ALXN, MDCA

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

CLGX : 81.79 (-1.29%)
CATM : 38.52 (-0.10%)
CHNG : 22.45 (-0.58%)
ALXN : 148.46 (+0.18%)
MDCA : 3.07 (-7.53%)
During Kidney Month, American Kidney Fund Marks Its 50th Anniversary by Honoring Patient Milestones

/ Fifty years ago, a small group of friends created a nonprofit that in its first year saved the lives of 79 people with kidney failure, and a mission was born. This Kidney Month, the American Kidney Fund...

ALXN : 148.46 (+0.18%)
AMGN : 221.91 (-0.91%)
DGX : 117.28 (+0.34%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds BFTL, ALXN, STPK, and BRPA Shareholders About Its Ongoing Investigations

, /PRNewswire/ --

BFTL : 2.9200 (-1.02%)
ALXN : 148.46 (+0.18%)
STPK : 26.41 (-5.75%)
BRPA : 28.20 (-9.67%)
Apellis' (APLS) Q4 Earnings Rise Y/Y, Pegcetacoplan in Focus

Apellis' (APLS) bottom line grows year over year in the fourth quarter of 2020 while revenues beat estimates. Main focus of the company is on lead pipeline candidate, pegcetacoplan.

ALXN : 148.46 (+0.18%)
LXRX : 6.66 (-7.24%)
NBRV : 1.7500 (-9.79%)
APLS : 45.65 (+0.29%)
Nasdaq ETF's Worst Day Since October: Stocks That Survived

The Nasdaq dropped 3.52% on Feb 25 for its worst session since October on rising rate worries. However, some stocks still remained in the green on that day or lost little.

CSCO : 44.56 (-1.26%)
ALXN : 148.46 (+0.18%)
ATVI : 91.54 (-2.32%)
MRNA : 132.30 (+0.82%)
MDLZ : 53.96 (+1.93%)
TMUS : 118.61 (-0.19%)
American Kidney Fund Announces 2021 Class of Corporate Members Aligned in Fighting Kidney Disease

The American Kidney Fund (AKF) today announced the 2021 class of Members in its . Corporate Members form a strategic partnership with AKF, helping AKF to fight on all fronts to save the lives of those...

ALXN : 148.46 (+0.18%)
AMGN : 221.91 (-0.91%)
APLS : 45.65 (+0.29%)
AUPH : 13.41 (-6.75%)
OMER : 17.72 (-11.18%)
DGX : 117.28 (+0.34%)
Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant...

ALXN : 148.46 (+0.18%)
ARCT : 45.54 (-9.98%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates the Following Companies on Behalf of Shareholders - MDCA, VIE, CLGX, ALXN, TCF

, /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:

MDCA : 3.07 (-7.53%)
VIE : 52.96 (-0.04%)
CLGX : 81.79 (-1.29%)
ALXN : 148.46 (+0.18%)
TCF : 46.42 (-0.81%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds GIX, ALXN, STPK, and BRPA Shareholders About Its Ongoing Investigations

, /PRNewswire/ --

GIX : 10.06 (+0.30%)
ALXN : 148.46 (+0.18%)
STPK : 26.41 (-5.75%)
BRPA : 28.20 (-9.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes...

See More

Key Turning Points

3rd Resistance Point 153.26
2nd Resistance Point 151.71
1st Resistance Point 150.08
Last Price 148.46
1st Support Level 146.90
2nd Support Level 145.35
3rd Support Level 143.72

See More

52-Week High 162.60
Last Price 148.46
Fibonacci 61.8% 128.25
Fibonacci 50% 117.64
Fibonacci 38.2% 107.02
52-Week Low 72.67

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar